Zoetis Inc. (NYSE:ZTS) Shares Sold by SVB Wealth LLC

SVB Wealth LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 6.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 67,588 shares of the company’s stock after selling 4,362 shares during the quarter. SVB Wealth LLC’s holdings in Zoetis were worth $11,717,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Chicago Capital LLC grew its stake in shares of Zoetis by 0.3% in the second quarter. Chicago Capital LLC now owns 274,140 shares of the company’s stock valued at $47,525,000 after buying an additional 949 shares in the last quarter. Isthmus Partners LLC grew its stake in shares of Zoetis by 0.7% in the second quarter. Isthmus Partners LLC now owns 67,888 shares of the company’s stock valued at $11,769,000 after buying an additional 482 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC grew its stake in shares of Zoetis by 1.9% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 5,276 shares of the company’s stock valued at $915,000 after buying an additional 98 shares in the last quarter. UNIVEST FINANCIAL Corp grew its stake in shares of Zoetis by 6.1% in the second quarter. UNIVEST FINANCIAL Corp now owns 22,649 shares of the company’s stock valued at $3,926,000 after buying an additional 1,306 shares in the last quarter. Finally, SFE Investment Counsel grew its stake in shares of Zoetis by 15.8% in the second quarter. SFE Investment Counsel now owns 26,947 shares of the company’s stock valued at $4,672,000 after buying an additional 3,680 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Stifel Nicolaus reissued a “buy” rating and issued a $200.00 price target on shares of Zoetis in a report on Tuesday, August 27th. Piper Sandler increased their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $217.11.

Zoetis Price Performance

Shares of NYSE ZTS traded up $2.64 during mid-day trading on Friday, reaching $189.23. The company had a trading volume of 2,710,102 shares, compared to its average volume of 2,661,613. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market cap of $85.73 billion, a PE ratio of 36.45, a P/E/G ratio of 2.87 and a beta of 0.88. The company has a 50-day moving average price of $181.22 and a two-hundred day moving average price of $174.57. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.41 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.